ATHA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ATHA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Athira Pharma does not have enough data to calculate Degree of Operating Leverage.
The historical data trend for Athira Pharma's Degree of Operating Leverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Athira Pharma Annual Data | ||||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Degree of Operating Leverage | Get a 7-Day Free Trial | - | - | - | - | - |
Athira Pharma Quarterly Data | ||||||||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | Mar25 | |
Degree of Operating Leverage | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Athira Pharma's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Athira Pharma's Degree of Operating Leverage distribution charts can be found below:
* The bar in red indicates where Athira Pharma's Degree of Operating Leverage falls into.
Athira Pharma's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:
Degree of Operating Leverage | = | % Change in EBIT** | / | % Change in Revenue |
= | ( -78.624 (Mar. 2025) / -125.011 (Mar. 2024) - 1 ) | / | ( 0 (Mar. 2025) / 0 (Mar. 2024) - 1 ) | |
= | -0.3711 | / | ||
= | N/A*** |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Athira Pharma (NAS:ATHA) Degree of Operating Leverage Explanation
Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.
A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.
Be Aware
The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.
Thank you for viewing the detailed overview of Athira Pharma's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.
Mark James Litton | officer: Chief Operating Officer | 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011 |
Mark Worthington | officer: General Counsel | C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL WA 98011 |
Kevin Church | officer: Vice President of Discovery | 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141 |
Rachel Lenington | officer: Chief Technology Officer | C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL WA 98011 |
Andrew Gengos | officer: See Below | 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367 |
Kelly A Romano | director | C/O DORMAN PRODUCTS, INC., 3400 EAST WALNUT STREET, COLMAR PA 18915 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Grant Pickering | director | C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070 |
James A Johnson | director | C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE, SEATTLE WA 98102 |
Glenna Mileson | officer: Chief Financial Officer | 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141 |
Hans Moebius | officer: Chief Medical Officer | 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141 |
Michael A. Panzara | director | 733 CONCORD AVENUE, CAMBRIDGE MA 02138 |
Barbara Kosacz | director | 3175 HANOVER STREET, PALO ALTO CA 94304 |
Joseph Edelman | director, 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Rtw Investments, Lp | 10 percent owner | 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014 |
From GuruFocus
By GuruFocus Research • 02-06-2024
By GuruFocus News • 05-13-2025
By GuruFocus Research • 06-26-2024
By Marketwired • 05-13-2025
By GuruFocus News • 11-01-2024
By GuruFocus Research • 02-06-2024
By Marketwired • 08-01-2024
By GlobeNewswire • 12-06-2024
By Marketwired • 07-09-2024
By GlobeNewswire • 05-17-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.